Apraclonidine and Hydrocodone and Guaifenesin Tablets
Determining the interaction of Apraclonidine and Hydrocodone and Guaifenesin Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:After using apraclonidine ophthalmic, some of the medication may be absorbed into the bloodstream and occasionally produce central nervous system side effects such as dizziness, drowsiness, and difficulty concentrating. Combining it with HYDROcodone or other medications that can also have these effects may increase the risk. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered. Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.
MANAGEMENT: Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.
- Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4
- "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.
- "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc, Cranbury, NJ.
Generic Name: apraclonidine ophthalmic
Brand name: Iopidine
Synonyms: Apraclonidine ophthalmic
Generic Name: guaifenesin / hydrocodone
Brand name: Xtrelus
Synonyms: Hydrocodone and Guaifenesin Oral Solution, Hydrocodone and Guaifenesin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Apraclonidine-Hydrocodone and homatropine
- Apraclonidine-Hydrocodone and Homatropine Syrup
- Apraclonidine-Hydrocodone and Homatropine Tablets
- Apraclonidine-Hydrocodone and ibuprofen
- Apraclonidine-Hydrocodone and Pseudoephedrine
- Apraclonidine-Hydrocodone Bitartrate
- Hydrocodone and Guaifenesin Tablets-Apraclonidine Hydrochloride
- Hydrocodone and Guaifenesin Tablets-Apraclonidine ophthalmic
- Hydrocodone and Guaifenesin Tablets-Apremilast
- Hydrocodone and Guaifenesin Tablets-Aprepitant
- Hydrocodone and Guaifenesin Tablets-Aprepitant Capsules
- Hydrocodone and Guaifenesin Tablets-Aprepitant Injection